Whereas Met inhibition alone exerted a limited effect on FRS2 phosphorylation in tumourspheres, Crizotinib was sufficient to reduce FRS2 phosphorylation in tumours to a level similar to FGFR inhibitor. The gene discussed is FRS2; the disease is neoplasm.